To assess the relative effectiveness of first-line treatments for patients with advanced EGFR-mutated NSCLC, multiple scores of RCTs and traditional pairwise meta-analyses were performed [14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.